Apple Inc.'s Steve Jobs

Apple Inc.'s Steve Jobs

Ryan Anson/Bloomberg

If Apple Inc.'s Steve Jobs’s third leave means the malignancy is back, his treatment options now include a wave of new drugs that add months on average to survival rates, doctors say.